Lumos Other Non Cash Items vs Begin Period Cash Flow Analysis
| LUMO Stock | USD 4.30 0.01 0.23% |
Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Other Non Cash Items and its Begin Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
Other Non Cash Items vs Begin Period Cash Flow
Other Non Cash Items vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Other Non Cash Items account and Begin Period Cash Flow. At this time, the significance of the direction appears to have weak relationship.
The correlation between Lumos Pharma's Other Non Cash Items and Begin Period Cash Flow is 0.34. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Other Non Cash Items and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of Lumos Pharma are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Other Non Cash Items i.e., Lumos Pharma's Other Non Cash Items and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.34 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Other Non Cash Items
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 484K | 874K | 1.0M | 671.3K | Depreciation And Amortization | 203K | 49K | 44K | 41.8K |
Lumos Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Lumos Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lumos Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Short Long Term Debt Total | 1.2M | 319K | 557K | 233K | 585K | 555.8K | |
| Other Current Liab | 10.2M | 5.6M | 3.8M | 6.0M | 5.6M | 5.8M | |
| Total Current Liabilities | 11.8M | 6.5M | 5.1M | 6.7M | 7.0M | 11.8M | |
| Total Stockholder Equity | 78.9M | 116.6M | 89.0M | 59.6M | 27.3M | 25.9M | |
| Property Plant And Equipment Net | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Net Debt | (89.3M) | (98.4M) | (94.3M) | (55.8M) | (34.5M) | (36.2M) | |
| Retained Earnings | (334.0M) | (66.0M) | (96.4M) | (127.5M) | (161.5M) | (169.6M) | |
| Accounts Payable | 475K | 244K | 612K | 275K | 890K | 845.5K | |
| Cash | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
| Non Current Assets Total | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
| Non Currrent Assets Other | 735K | (584K) | (635K) | (283K) | (325.5K) | (341.7K) | |
| Cash And Short Term Investments | 90.5M | 98.7M | 94.8M | 67.4M | 36.1M | 34.3M | |
| Net Receivables | 824K | 26.3M | 128K | 223K | 210K | 199.5K | |
| Common Stock Total Equity | 372K | 373K | 12K | 83K | 74.7K | 71.0K | |
| Common Stock Shares Outstanding | 144.7K | 6.8M | 8.3M | 8.4M | 8.1M | 4.1M | |
| Liabilities And Stockholders Equity | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Non Current Liabilities Total | 6.9M | 6.1M | 6M | 6.2M | 6.3M | 6.0M | |
| Other Current Assets | 3.0M | 3.5M | 4.7M | 4.4M | 3.7M | 6.2M | |
| Other Stockholder Equity | 412.5M | 311.5M | 185.3M | 187.0M | 188.7M | 223.2M | |
| Total Liab | 17.9M | 12.5M | 11.3M | 12.7M | 13.3M | 21.4M | |
| Property Plant And Equipment Gross | 457K | 584K | 635K | 283K | 603K | 572.9K | |
| Total Current Assets | 94.4M | 128.4M | 99.7M | 72.0M | 40.0M | 38.0M | |
| Accumulated Other Comprehensive Income | (6.6M) | (7.0M) | (63.5M) | (129.0M) | 0.0 | (9K) | |
| Short Term Debt | 1.1M | 638K | 704K | 466K | 564K | 579.2K | |
| Common Stock | 373K | 374K | 83K | 82K | 81K | 77.0K | |
| Net Tangible Assets | 78.9M | 116.6M | 89.0M | 59.6M | 68.5M | 104.9M | |
| Retained Earnings Total Equity | (237.5M) | (291.0M) | (334.0M) | (66.0M) | (59.4M) | (62.4M) | |
| Capital Surpluse | 389.8M | 407.2M | 414.0M | 182.5M | 209.9M | 293.4M | |
| Property Plant Equipment | 1.6M | 335K | 635K | 283K | 254.7K | 242.0K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.